Evidence map›Paper›PMID 38347963›Full record

ArticlePathogens & immunity2023

Stable Levels of Antibodies Against Unrelated Toxoid Vaccines After COVID-19: COVID-19 Infection Does Not Affect Toxoid Vaccine Antibody Levels.

Suvi T Jokiranta, Simo Miettinen, Sami Salonen, Lauri Kareinen, Ruut Uusitalo, Essi M Korhonen, Jenni Virtanen, Ilkka Kivistö, Kirsi Aaltonen, Dina A Mosselhy and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens & immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Suvi T JokirantaDepartment of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Simo MiettinenViral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Sami SalonenHUS Diagnostic Center, Clinical Microbiology, Helsinki University Hospital, Helsinki, Finland.
Lauri KareinenDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Ruut UusitaloDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Essi M KorhonenDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Jenni VirtanenDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Ilkka KivistöDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Kirsi AaltonenDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Dina A MosselhyDepartment of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Tinja LääveriInfectious Diseases, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Anu KanteleHuman Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
T Petteri ArstilaDepartment of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Hanna JarvaDepartment of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
Olli VapalahtiViral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, Finland.
Santtu HeinonenNew Children's Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eliisa KekäläinenDepartment of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lymphopenia is common in COVID-19. This has raised concerns that COVID-19 could affect the immune system akin to measles infection, which causes immune amnesia and a reduction in protective antibodies. Methods: We recruited COVID-19 patients (n = 59) in Helsinki, Finland, and collected plasma samples on 2 to 3 occasions during and after infection. We measured IgG antibodies to diphtheria toxin, tetanus toxoid, and pertussis toxin, along with total IgG, SARS-CoV-2 spike protein IgG, and neutralizing antibodies. We also surveyed the participants for up to 17 months for long-term impaired olfaction as a proxy for prolonged post-acute COVID-19 symptoms. Results: No significant differences were found in the unrelated vaccine responses while the serological response against COVID-19 was appropriate. During the acute phase of the disease, the SARSCoV-2 IgG levels were lower in outpatients when compared to inpatients. SARS-CoV-2 serology kinetics matched expectations. In the acute phase, anti-tetanus and anti-diphtheria IgG levels were lower in patients with prolonged impaired olfaction during follow up than in those without. Conclusions: We could not detect significant decline in overall humoral immunity during or after COVID-19 infection. In severe COVID-19, there appears to be a temporary decline in total IgG levels.

Indexed as

AntibodiesCOVID-19HumoralImmunityPost-acute COVID-19 syndromeVaccines

Identifiers

PMID38347963
PMCPMC10860543
OpenAlexW4391598026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.